Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E4HB
|
|||
| Former ID |
DNC011207
|
|||
| Drug Name |
2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole
|
|||
| Synonyms |
CHEMBL220495; 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole; AC1P6Q43; SCHEMBL19017688; ZINC7350105; BDBM50326652; AKOS005139675; ST51067929; N-(cyclohexylideneamino)-4-phenyl-thiazol-2-amine; 1-cyclohexylidene-2-(4-phenylthiazol-2-yl)hydrazine; N-(cyclohexylideneamino)-4-phenyl-1,3-thiazol-2-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H17N3S
|
|||
| Canonical SMILES |
C1CCC(=NNC2=NC(=CS2)C3=CC=CC=C3)CC1
|
|||
| InChI |
1S/C15H17N3S/c1-3-7-12(8-4-1)14-11-19-15(16-14)18-17-13-9-5-2-6-10-13/h1,3-4,7-8,11H,2,5-6,9-10H2,(H,16,18)
|
|||
| InChIKey |
RQMWJSWLKXHIEZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.